Home / Themes / Biotech '25: Cancer Immunotherapy
Last updated
Theme thesis · 3/5 sections · Tickers 6 with notes · 13 pending
Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).
Developers and commercial manufacturers of cancer immunotherapies harness the patient's immune system to recognize and destroy malignant cells through checkpoin
Developers and commercial manufacturers of cancer immunotherapies harness the patient's immune system to recognize and destroy malignant cells through checkpoint blockade, T-cell recruitment, cytokine stimulation and therapeutic cancer vaccination. Revenue and pipeline opportunities depend on extending durable immune responses into additional tumor types, earlier treatment lines and combination regimens, while overcoming immune resistance and limiting systemic toxicity. The basket excludes engineered cell therapies and cytotoxic antibody-drug conjugates, which have distinct treatment mechanisms and economics.
Checkpoint inhibitors gain additional approvals in earlier-stage cancer, adjuvant treatment and biomarker-selected populations, increasing the number of eligible patients and potentially reducing recurrence after initial therapy.
CD3-targeting bispecific antibodies, masked T-cell engagers and novel immune checkpoint combinations extend effective immunotherapy into solid tumors and hematologic cancers that previously responded poorly to conventional PD-1 blockade.
Personalized neoantigen vaccines, cytokine agonists and new immunomodulatory combinations improve response durability or overcome acquired resistance, creating opportunities for differentiated regimens alongside established checkpoint inhibitors.
Clinical resistance caused by antigen loss, immunosuppressive tumor microenvironments and insufficient T-cell infiltration limits durable responses, particularly in solid tumors that have historically responded poorly to immunotherapy.
Immune-related adverse events, cytokine release syndrome and other serious inflammatory toxicities restrict dosing, treatment combinations and eligible patient populations, potentially offsetting efficacy advantages of intensified immune activation.
Competition among PD-1 and PD-L1 inhibitors, biosimilars, alternative checkpoint combinations and competing bispecific platforms compresses pricing, while negative confirmatory trials and payer restrictions constrain commercial expansion.
patient experiences with immunotherapy, clinical trial discussions, side effects, treatment efficacy, emotional support
caregiver perspectives on immunotherapy, treatment decisions, managing side effects, family support
specific discussions on melanoma immunotherapy, drug experiences (e.g., Keytruda, Opdivo), recurrence, side effect management
general patient discussions, treatment comparisons, practical advice, community support
American Cancer Society community forums, broad cancer discussions, treatment options, research updates
Matchedfred · access=api · map_only
Metric/field HCPIDRUG
Cadence monthly
Why it matters Indicates overall spending on prescription drugs, directly impacting revenue potential for biotech firms in the oncology and immunotherapy space.
Signal to watch Increasing trend suggests a growing market and higher revenue potential for pharmaceutical products.
Confidence: high
Matchedfred · access=api · map_only
Metric/field RDPCE
Cadence monthly
Why it matters Reflects the investment appetite of the private sector in innovation, which is crucial for R&D-heavy biotech companies focused on new therapies.
Signal to watch Sustained or increasing R&D spending indicates continued innovation and pipeline development within the broader economy.
Confidence: high
Matchedfred · access=api · map_only
Metric/field GS10
Cadence monthly
Why it matters Serves as a benchmark for long-term borrowing costs, impacting financing for R&D, clinical trials, and potential M&A activities for biotech companies.
Signal to watch Lower yields reduce borrowing costs, potentially encouraging investment and M&A; higher yields increase the cost of capital.
Confidence: high
Not in registryaccess=api
Metric/field CUUR0000SAM
Cadence monthly
Why it matters Measures inflation specifically within the medical care sector, impacting operational costs for biotech firms and potential pricing power for their products.
Signal to watch Moderate inflation suggests a stable pricing environment; high inflation could pressure margins or lead to increased scrutiny on drug pricing.
Confidence: high
Matchedfred · access=api · map_only
Metric/field GDPC1
Cadence monthly
Why it matters General economic health influences overall healthcare spending, patient access to treatments, and government budgets allocated to healthcare and research.
Signal to watch Strong GDP growth typically correlates with higher healthcare spending and a more favorable investment climate for innovative therapies.
Confidence: medium
Not in registry
Metric/field Number of new studies registered with 'Oncology' OR 'Immunotherapy' in 'Condition or disease' or 'Intervention/treatment' fields (status: 'Recruiting' or 'Not yet recruiting')
Cadence daily
Why it matters Indicates the pace of new research and development in the core theme areas, signaling future pipeline potential and scientific activity.
Signal to watch An increasing number of new trials suggests a robust and expanding R&D landscape, pointing to future innovation.
Confidence: high
Not in registry
Metric/field Number of new drug approvals (NDA/BLA) for oncology or immunotherapy indications (search 'Oncology' or 'Immunotherapy' in 'Therapeutic Area' or 'Indication')
Cadence event_driven
Why it matters Directly measures regulatory success and market entry for new treatments, which is crucial for revenue generation and validating R&D efforts.
Signal to watch A higher number of approvals indicates a favorable regulatory environment and successful progression of new therapies to market.
Confidence: high
Not in registry
Metric/field Search interest index for 'cancer immunotherapy' (worldwide or US)
Cadence daily
Why it matters Reflects public and patient interest in the theme's core technologies, potentially indicating future demand, awareness, and engagement with new treatments.
Signal to watch Rising search interest suggests increasing public awareness and potential future adoption or discussion around these therapies.
Confidence: medium
Not in registry
Metric/field Number of new grants awarded with 'oncology' or 'immunotherapy' in project title/abstract
Cadence monthly
Why it matters Indicates government funding and scientific focus on key research areas, often serving as a precursor to future drug development and innovation.
Signal to watch Increased grant funding suggests sustained government support and scientific momentum in the field of oncology and immunotherapy.
Confidence: high
Not in registry
Metric/field Number of new patents granted in IPC classes related to oncology/immunotherapy (e.g., A61K39/00 for vaccines/immunostimulants, A61P35/00 for antineoplastic agents)
Cadence weekly
Why it matters Reflects innovation and intellectual property protection in the biotech space, which is crucial for competitive advantage and future market exclusivity.
Signal to watch A growing number of relevant patents indicates a healthy pace of innovation and potential for new, protected therapies.
Confidence: high
Matchediqvia_prescription_rx_data · access=file · map_only
Metric/field Weekly New-to-Brand Prescriptions (NBRx) for key oncology and immunotherapy drug classes (e.g., PD-1 inhibitors, CAR-T therapies)
Cadence irregular
Why it matters Provides real-time insight into the adoption and market penetration of new and existing drugs, directly impacting revenue and market share for theme members.
Signal to watch Increasing NBRx indicates strong market uptake and favorable physician prescribing trends for relevant therapies.
Confidence: high
Not in registry
Metric/field Probability of Success (PoS) changes for Phase 2 and Phase 3 oncology/immunotherapy assets
Cadence monthly
Why it matters Quantifies the likelihood of a drug successfully completing clinical trials and gaining regulatory approval, a key value driver for biotech companies.
Signal to watch Upward revisions in PoS for late-stage assets signal increased confidence in future approvals and significant market potential.
Confidence: high
Not in registry
Metric/field Physician adoption intent and prescribing patterns for recently approved or emerging oncology/immunotherapy drugs
Cadence monthly
Why it matters Gauges the willingness of healthcare providers to prescribe new therapies, directly influencing market penetration and sales volumes.
Signal to watch High or increasing adoption intent suggests strong market acceptance and future sales growth for specific treatments.
Confidence: high
Not in registry
Metric/field Changes in formulary coverage status (e.g., preferred, restricted, non-covered) for key oncology/immunotherapy drugs across major US payers
Cadence monthly
Why it matters Formulary placement dictates patient access and reimbursement, critically impacting drug sales volumes and market reach.
Signal to watch Improved formulary coverage (e.g., moving to preferred status) indicates broader patient access and higher sales potential.
Confidence: high
Matchedclarivate_scientific_publications_citations · access=file · map_only
Metric/field Volume and sentiment of publications, presentations, and social media mentions by top oncology/immunotherapy KOLs regarding emerging therapies or specific companies
Cadence irregular
Why it matters KOL influence can significantly impact the perception, adoption, and ultimate success of new drugs and technologies in the medical community.
Signal to watch Positive sentiment and increased activity from KOLs regarding a specific therapy or company can signal strong future prospects and market acceptance.
Confidence: medium
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type | Catalyst Source |
|---|---|---|---|---|---|---|---|---|---|
| AMGN_fe4d51bf | We will update you on those discussions as necessary. | 2026-04-24 | 2026-12-31 | Resolution of ongoing discussions with the FDA regarding TABNIO's (avacopan) following a voluntary withdrawal request related to primary endpoint result readjudication. | The outcome will determine the future commercial viability of TABNIO's, impacting Amgen's rare disease portfolio and potentially leading to a re-evaluation of the product's sales trajectory. | Ticker | 2026-02-03 | earnings_transcript | AMGN (ticker) |
| MRK_5a30de4f | evening of Monday, October 26, at the European Society for Medical Oncology in Madrid | 2026-10-26 | 2026-10-26 | Presentation of detailed results from the Phase III TroFuse-005 study of sac-TMT in advanced or recurrent endometrial cancer at ESMO. | Detailed data will provide further insight into the efficacy and safety of sac-TMT, a key pipeline asset with potential for first-mover advantage, and inform future development and commercialization strategies. | Ticker | 2026-08-04 | earnings_transcript | MRK (ticker) |
| MRK_bcd577c2 | second half of 2026 | 2026-09-01 | 2026-12-31 | Second readout from the ATLAS-UC trial for tulisokibart in moderately to severely active ulcerative colitis. | This readout, combined with the earlier induction study, will form the basis of a regulatory filing, reinforcing confidence in the program's potential and expanding Merck's immunology portfolio. | Ticker | 2026-08-04 | earnings_transcript | MRK (ticker) |
| REGN_76369989 | before the end of the year | 2026-10-01 | 2026-12-31 | FDA approval of the EYLEA HD prefilled syringe. | This product enhancement is expected to drive even further adoption of EYLEA HD, strengthening its competitive position and contributing to sales growth. | Ticker | 2026-07-30 | earnings_transcript | REGN (ticker) |
| REGN_07f81147 | later this year | 2026-10-01 | 2026-12-31 | Initiation of multiple Phase III studies for olatorepatide in patients with obesity and in patients with obesity and type 2 diabetes. | Marks significant progress in Regeneron's obesity portfolio, positioning the company to enter a high-growth market with a potentially differentiated dual GLP-GIP receptor agonist. | Ticker | 2026-07-30 | earnings_transcript | REGN (ticker) |
| REGN_0f639ad7 | November of this year | 2026-11-01 | 2026-11-30 | FDA decision on the New Drug Application (NDA) for cemdisiran, an siRNA targeting C5, in generalized myasthenia gravis (gMG). | Potential approval would introduce a highly differentiated treatment option for gMG patients with a convenient quarterly subcutaneous dosing profile, expanding Regeneron's rare disease portfolio. | Ticker | 2026-07-30 | earnings_transcript | REGN (ticker) |
| RHHBY_275c123d | November 15 | 2026-11-15 | 2026-11-15 | U.S. FDA PDUFA date for Gazyva in membranous nephropathy (MN). | Approval would position Gazyva as the first approved treatment for MN, potentially establishing a new standard of care and expanding its immunology sales. | Ticker | 2026-07-23 | earnings_transcript | RHHBY (ticker) |
| RHHBY_547ab592 | November 30 | 2026-11-30 | 2026-11-30 | U.S. FDA PDUFA date for Ladera in adjuvant ER-positive HER2-negative breast cancer. | A positive FDA decision would enable the launch of Ladera, expanding Roche's oncology portfolio and addressing a significant unmet need in breast cancer treatment. | Ticker | 2026-07-23 | earnings_transcript | RHHBY (ticker) |
| RHHBY_3ff530ea | December 18 | 2026-12-18 | 2026-12-18 | U.S. FDA PDUFA date for Avera. | A positive FDA decision for Avera would further strengthen Roche's breast cancer franchise, offering another treatment option and contributing to future revenue. | Ticker | 2026-07-23 | earnings_transcript | RHHBY (ticker) |
2 stories tagged to this theme — Narrative Radar and editorial picks.
